Hypertension

There are approximately 1.28 billion hypertension patients in the world and approximately 245 million hypertension patients in China. Epidemiological surveys show that the awareness rate, treatment rate and control rate of hypertension in China are 51.6%, 45.8% and 16.8%, respectively, which are all relatively low.

The Renin-Angiotensin-Aldosterone System plays a critical role to regulate the fluids and electrolytes balances in humans. Inhibition of aldosterone synthase has been proven effective at clinical setting for numerous cardiometabolic disease. 

JX09 (formally called PB6440) is a next-generation, highly selective aldosterone synthase inhibitor. Preclinical data suggest that JX09 offers strong potency inhibiting aldosterone synthase, with very little impact on the biological functions of a homologous enzyme that is key to cortisol synthesis. The high potency and selectivity make JX09 a potential best-in-class drug candidate. 

Reference: 

• Lee J, Schotzinger J, et al. The Selective Aldosterone Synthase Inhibitor PB6440 Normalizes Blood Pressure In A Human Aldosterone Synthase-Transgenic Mouse Model Of Hypertension, Hypertension 2022, 79, A121.

• Pitt B, Bhatt D, et al, Inhibition Of Aldosterone Synthesis In Non-human Primates By PB6440, The Novel Highly Selective And Potent CYP11B2 Inhibitor, Hypertension 2020, 76, AP233.

• NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, The Lancet 2021, 398, 10304, 957-980.

• National Center for Cardiovascular Diseases, et al. Clinical practice guidelines for the management of hypertension in China. China J Cardiol, 2022, 50(11): 1050-1095.         

• Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results from the China hypertension survey, 2012– 2015. Circulation 2018; 137: 2344–2356.